Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + BGB-A1217 versus tislelizumab + placebo as second-line treatment for PD-L1-positive esophageal squamous cell carcinoma
MOH_2022-05-16_010788Phase 2Not yet recruiting
- Sponsor
- BeiGene
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tislelizumab and ociperlimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by BeiGene. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
tislelizumabociperlimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on MOH_2022-05-16_010788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-16_010788.